COVID-19 and Bacillus Calmette-Guérin: What is the Link?

Eur Urol Oncol. 2020 Jun;3(3):259-261. doi: 10.1016/j.euo.2020.04.001. Epub 2020 Apr 13.

Abstract

The debate around the role of vaccination with Bacillus Calmette-Guérin has revived right in the time of the Coronavirus disease 19 pandemic. Since Bacillus Calmette-Guérin is one of the most commonly delivered therapies in urology, in this editorial we discuss some points that we think will be of interest and guidance to practicing urologists during this public health emergency.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / supply & distribution
  • BCG Vaccine / administration & dosage*
  • BCG Vaccine / adverse effects
  • BCG Vaccine / supply & distribution
  • Betacoronavirus / drug effects*
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity
  • COVID-19
  • COVID-19 Vaccines
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / immunology
  • Coronavirus Infections / prevention & control*
  • Coronavirus Infections / virology
  • Europe / epidemiology
  • Health Services Accessibility*
  • Humans
  • Immunization* / adverse effects
  • Pandemics / prevention & control*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / prevention & control*
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Urologic Neoplasms / drug therapy*
  • Urologic Neoplasms / epidemiology
  • Urologic Neoplasms / immunology
  • Viral Vaccines / administration & dosage*
  • Viral Vaccines / adverse effects
  • Viral Vaccines / supply & distribution

Substances

  • Antineoplastic Agents
  • BCG Vaccine
  • COVID-19 Vaccines
  • Viral Vaccines